TDMS Study 93026-06 Pathology Tables
NTP Experiment-Test: 93026-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DECALIN Date: 04/11/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:23:40
Final#1, Revision#2
Facility: Battelle Northwest
Chemical CAS #: 91-17-8
Lock Date: 01/04/01
Cage Range: All
Reasons For Removal: 25022 Accidently Killed 25019 Moribund Sacrifice
25020 Natural Death 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 93026-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DECALIN Date: 04/11/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:23:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 25 PPM 100 PPM 400 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 2 7 3 6
Moribund Sacrifice 10 15 11 8
Accidently Killed 1
Survivors
Moribund Sacrifice 1
Terminal Sacrifice 37 28 35 35
Animals Examined Microscopically 49 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (49) (50) (50) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Gallbladder (41) (40) (40) (38)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (3%)
Intestine Large, Cecum (48) (43) (47) (46)
Leiomyoma 1 (2%)
Intestine Small, Duodenum (48) (43) (47) (47)
Polyp Adenomatous 1 (2%)
Intestine Small, Ileum (47) (45) (49) (47)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Liver (49) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Hepatoblastoma 1 (2%)
Hepatocellular Carcinoma 4 (8%) 15 (30%) 6 (12%) 5 (10%)
Hepatocellular Carcinoma, Multiple 1 (2%)
Hepatocellular Adenoma 4 (8%) 11 (22%) 7 (14%) 14 (28%)
Hepatocellular Adenoma, Multiple 3 (6%) 2 (4%) 1 (2%) 3 (6%)
Hepatocholangiocarcinoma 1 (2%)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Mesentery (17) (18) (12) (18)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (6%)
Sarcoma, Metastatic, Skin 1 (6%)
Page 2
NTP Experiment-Test: 93026-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DECALIN Date: 04/11/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:23:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 25 PPM 100 PPM 400 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Pancreas (49) (47) (50) (49)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Salivary Glands (49) (50) (50) (50)
Stomach, Forestomach (49) (49) (50) (47)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Squamous Cell Carcinoma 1 (2%) 1 (2%)
Stomach, Glandular (48) (47) (50) (47)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Tongue (1)
Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (2)
Aorta, Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (50%)
Heart (49) (50) (50) (50)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (49) (50) (50) (49)
Subcapsular, Adenoma 1 (2%)
Adrenal Medulla (48) (50) (50) (49)
Pheochromocytoma Benign 2 (4%) 2 (4%) 1 (2%)
Islets, Pancreatic (49) (47) (50) (49)
Adenoma 1 (2%) 1 (2%)
Pituitary Gland (49) (49) (49) (50)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Pars Distalis, Adenoma 13 (27%) 8 (16%) 10 (20%) 17 (34%)
Pars Intermedia, Adenoma 1 (2%) 1 (2%) 2 (4%) 2 (4%)
Thyroid Gland (49) (49) (50) (47)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 93026-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DECALIN Date: 04/11/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:23:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 25 PPM 100 PPM 400 PPM
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (49) (49) (49) (48)
Carcinoma, Metastatic, Uterus 1 (2%)
Cystadenoma 1 (2%) 3 (6%) 2 (4%)
Granulosa Cell Tumor Malignant 1 (2%)
Granulosa Cell Tumor Benign 1 (2%) 1 (2%) 1 (2%)
Granulosa-Theca Tumor Malignant 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Luteoma 1 (2%)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Tubulostromal Adenoma 1 (2%)
Uterus (49) (49) (50) (49)
Carcinoma 1 (2%) 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Polyp Stromal 2 (4%) 3 (6%)
Sarcoma Stromal 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (50) (50) (48)
Hemangiosarcoma 1 (2%) 1 (2%)
Lymph Node (5) (2) (4) (1)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (25%)
Iliac, Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (25%)
Lymph Node, Bronchial (41) (45) (47) (44)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Page 4
NTP Experiment-Test: 93026-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DECALIN Date: 04/11/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:23:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 25 PPM 100 PPM 400 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Lymph Node, Mandibular (36) (40) (37) (41)
Carcinoma, Metastatic, Harderian Gland 1 (3%)
Lymph Node, Mesenteric (47) (47) (50) (47)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Lymph Node, Mediastinal (43) (42) (43) (46)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Spleen (49) (47) (50) (48)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Thymus (48) (48) (48) (47)
Thymoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (48) (50) (50) (50)
Carcinoma 1 (2%) 2 (4%) 2 (4%)
Skin (49) (50) (50) (50)
Basal Cell Carcinoma 1 (2%)
Mast Cell Tumor Benign 1 (2%)
Neural Crest Tumor 1 (2%)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Fibrous Histiocytoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Sarcoma 2 (4%) 2 (4%) 2 (4%) 1 (2%)
Subcutaneous Tissue, Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 93026-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DECALIN Date: 04/11/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:23:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 25 PPM 100 PPM 400 PPM
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (49) (50) (50) (50)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Osteoma 1 (2%)
Skeletal Muscle (2)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (49) (50) (50) (50)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (49) (50) (50) (49)
Lung (49) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 1 (2%) 4 (8%) 4 (8%)
Alveolar/Bronchiolar Carcinoma 6 (12%) 3 (6%) 1 (2%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Uterus 1 (2%)
Hemangiosarcoma, Metastatic, Liver 1 (2%)
Hemangiosarcoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 1 (2%) 2 (4%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
Mediastinum, Sarcoma, Metastatic, Skin 1 (2%)
Nose (49) (50) (50) (49)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Pleura (1) (1)
Sarcoma, Metastatic, Uncertain Primary Site 1 (100%)
____________________________________________________________________________________________________________________________________
Page 6
NTP Experiment-Test: 93026-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DECALIN Date: 04/11/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:23:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 25 PPM 100 PPM 400 PPM
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (2) (1) (2)
Carcinoma, Metastatic, Uncertain Primary Site 1 (50%)
Harderian Gland (4) (4) (5) (3)
Adenoma 3 (75%) 4 (100%) 2 (40%) 2 (67%)
Carcinoma 1 (25%) 3 (60%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Urinary Bladder (49) (46) (49) (47)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(49) *(50) *(50) *(50)
Lymphoma Malignant 11 (22%) 8 (16%) 13 (26%) 14 (28%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 7
NTP Experiment-Test: 93026-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DECALIN Date: 04/11/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:23:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 25 PPM 100 PPM 400 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 39 40 42 41
Total Primary Neoplasms 63 70 67 84
Total Animals with Benign Neoplasms 28 25 27 34
Total Benign Neoplasms 35 31 33 52
Total Animals with Malignant Neoplasms 22 28 28 26
Total Malignant Neoplasms 28 39 33 32
Total Animals with Metastatic Neoplasms 3 5 5 3
Total Metastatic Neoplasm 4 23 23 9
Total Animals with Malignant Neoplasms 2 2
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 8
NTP Experiment-Test: 93026-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DECALIN Date: 04/11/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:23:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 25 PPM 100 PPM 400 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 7 7 7 5
Natural Death 3 2 7 11
Survivors
Terminal Sacrifice 39 41 35 33
Moribund Sacrifice 1
Natural Death 1 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (42) (40) (41) (40)
Intestine Large, Cecum (48) (48) (49) (46)
Polyp Adenomatous 1 (2%)
Intestine Small, Duodenum (47) (48) (47) (43)
Carcinoma 1 (2%)
Intestine Small, Jejunum (46) (48) (47) (43)
Carcinoma 1 (2%) 1 (2%)
Liver (50) (50) (50) (50)
Cholangioma 1 (2%)
Hemangiosarcoma 1 (2%) 3 (6%) 2 (4%)
Hepatoblastoma 1 (2%) 1 (2%)
Hepatocellular Carcinoma 10 (20%) 7 (14%) 8 (16%) 11 (22%)
Hepatocellular Carcinoma, Multiple 2 (4%)
Hepatocellular Adenoma 16 (32%) 16 (32%) 9 (18%) 17 (34%)
Hepatocellular Adenoma, Multiple 6 (12%) 6 (12%) 5 (10%) 10 (20%)
Histiocytic Sarcoma 1 (2%)
Liposarcoma, Metastatic, Mesentery 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Mesentery (14) (11) (10) (15)
Liposarcoma 1 (7%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (7%)
Pancreas (49) (50) (50) (49)
Liposarcoma, Metastatic, Mesentery 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 2 (4%)
Salivary Glands (50) (50) (50) (49)
Stomach, Forestomach (49) (50) (49) (50)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Page 9
NTP Experiment-Test: 93026-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DECALIN Date: 04/11/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:23:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 25 PPM 100 PPM 400 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Stomach, Glandular (49) (49) (48) (48)
Liposarcoma, Metastatic, Mesentery 1 (2%)
Tooth (23) (26) (22) (21)
Sarcoma, Metastatic, Uncertain Primary Site 1 (5%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%)
Hemangiosarcoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (49) (50) (50) (50)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Subcapsular, Adenoma 2 (4%) 1 (2%) 4 (8%)
Adrenal Medulla (49) (50) (50) (50)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Islets, Pancreatic (49) (50) (50) (49)
Adenoma 1 (2%) 2 (4%) 2 (4%)
Pituitary Gland (48) (50) (50) (49)
Pars Distalis, Adenoma 1 (2%) 1 (2%)
Thyroid Gland (48) (48) (49) (49)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1)
Hemangiosarcoma, Metastatic, Liver 1 (100%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 93026-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DECALIN Date: 04/11/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:23:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 25 PPM 100 PPM 400 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Coagulating Gland (1)
Adenoma 1 (100%)
Epididymis (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Preputial Gland (49) (49) (50) (50)
Hemangiosarcoma 2 (4%)
Prostate (48) (50) (50) (50)
Seminal Vesicle (49) (50) (50) (50)
Liposarcoma, Metastatic, Mesentery 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Testes (50) (50) (50) (50)
Interstitial Cell, Adenoma 3 (6%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (50) (50) (48)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node (1) (3) (1)
Lymph Node, Bronchial (42) (36) (40) (41)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%) 2 (5%)
Liposarcoma, Metastatic, Mesentery 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 2 (5%)
Lymph Node, Mandibular (31) (36) (32) (22)
Carcinoma, Metastatic, Harderian Gland 1 (3%)
Liposarcoma, Metastatic, Mesentery 1 (5%)
Lymph Node, Mesenteric (49) (48) (50) (47)
Histiocytic Sarcoma 1 (2%)
Liposarcoma, Metastatic, Mesentery 1 (2%)
Plasma Cell Tumor Malignant 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 2 (4%)
Lymph Node, Mediastinal (41) (36) (42) (35)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%)
Sarcoma, Metastatic, Uncertain Primary Site 2 (6%)
Spleen (49) (50) (50) (49)
Hemangiosarcoma 3 (6%) 2 (4%)
Thymus (44) (44) (42) (40)
Carcinoma, Metastatic, Uncertain Primary Site 1 (3%)
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 93026-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DECALIN Date: 04/11/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:23:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 25 PPM 100 PPM 400 PPM
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (2)
Liposarcoma, Metastatic, Mesentery 1 (50%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (50) (50) (50) (50)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 6 (12%) 5 (10%) 4 (8%) 2 (4%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (4%)
Alveolar/Bronchiolar Carcinoma 6 (12%) 7 (14%) 6 (12%) 12 (24%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (4%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 2 (4%)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Hemangiosarcoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (6%) 1 (2%) 4 (8%) 5 (10%)
Histiocytic Sarcoma 1 (2%)
Liposarcoma, Metastatic, Mesentery 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 2 (4%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 2 (4%)
Pleura (1)
Sarcoma, Metastatic, Uncertain Primary Site 1 (100%)
____________________________________________________________________________________________________________________________________
Page 12
NTP Experiment-Test: 93026-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DECALIN Date: 04/11/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:23:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 25 PPM 100 PPM 400 PPM
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (9) (5) (5) (5)
Adenoma 6 (67%) 2 (40%) 4 (80%) 2 (40%)
Carcinoma 3 (33%) 1 (20%) 1 (20%) 1 (20%)
Bilateral, Adenoma 2 (40%) 1 (20%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (50) (50) (49)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Urinary Bladder (49) (50) (49) (49)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%)
Lymphoma Malignant 3 (6%) 3 (6%) 4 (8%) 4 (8%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 13
NTP Experiment-Test: 93026-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DECALIN Date: 04/11/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:23:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 25 PPM 100 PPM 400 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 43 39 37 42
Total Primary Neoplasms 69 64 52 75
Total Animals with Benign Neoplasms 32 27 22 32
Total Benign Neoplasms 42 35 25 41
Total Animals with Malignant Neoplasms 23 20 23 23
Total Malignant Neoplasms 27 29 27 34
Total Animals with Metastatic Neoplasms 5 1 6 10
Total Metastatic Neoplasm 6 1 7 48
Total Animals with Malignant Neoplasms 2
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 14
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------